Figure 6. The TAB3 O-GlcNAcylation is correlated with the poorer prognosis in TNBC patients.

(A) Representative negative and positive IHC staining for TAB3 expression and O-GlcNAcylated TAB3 in the sections from human breast cancer samples. Scale bars represent 50 mm. (B) Kaplan-Meier survival curve of breast cancer patients with lowand high TAB3 expression (a) and its O-GlcNAcylation (b) (p < 0.001 by log-rank test). Median follow-up period of 60 months. The number of surviving patients stratified to the follow-up periods is indicated below the graph.